The Claim
Vitamin K2 supplementation at 360 μg three times weekly for 18 months does not significantly reduce aortic valve calcification, arterial stiffness (cfPWV or AIx), or major adverse cardiac events in hemodialysis patients, despite lowering dp-ucMGP levels.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In hemodialysis patients, taking 360 micrograms of vitamin K2 three times a week for 18 months does not reduce calcification of the aortic valve, stiffness of the arteries, or serious heart events, even though it lowers dp-ucMGP levels.
See the scientific wording
Vitamin K2 supplementation at 360 μg three times weekly for 18 months does not significantly reduce aortic valve calcification, arterial stiffness (cfPWV or AIx), or major adverse cardiac events in hemodialysis patients, despite lowering dp-ucMGP levels.
Vitamin K2 activates a protein that blocks calcium from building up in blood vessels, but in people with kidney failure, this activation does not stop calcium from hardening heart valves or stiffening arteries, even though the protein becomes more active.
What the research says
1 studyTaking vitamin K2 pills as described didn't help stop calcium buildup in heart valves or stiffening of arteries in dialysis patients, even though it improved a blood marker. Heart problems didn't get any less common either.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.